There can be little doubt that the cost of AIDS, in human suffering in Africa, America and Europe, is a major concern for public health. But does AIDS in Britain justify, or need the current attention about, the cost to the health service of its treatment? I am increasingly concerned that the AIDS industry of research proposals and bids for money may in some cases be counterproductive and generally oflittle help.
Let no one doubt my support for measures to prevent the spread ofRN in Britain. Prevention is better than cure because of its benefits to the health of those potentially at risk. It is also not likely to be expensive, given the low cost of condoms and free hypodermic needles. Behaviour changes can even be free!! The challenge for prevention is not the cost, but the complexity of changing the behaviour of key groups, some of whom may not share the values of the majority. Surely the potential consequences of further spread of AIDS are clear enough without repeating rather crude and ever-larger estimates of what it is costing us to treat.
And what will AIDS cost to treat? To answer this question for future years requires an estimate of the services to be provided to each case and the number of cases. Estimates of the latter abound, but they offer a wide range of possible future scenarios.IfHIV does not spread rapidly beyond those currently infected, we can make some predictions based on estimates of the current HIV prevalence and the proportion of mv cases. These suggest that a possible 5000 cases per year of AIDS may be occurring in the 1990s in Britain. If this is combined with a recent cost projection of £27 000 per case, an implied annual cost to the NHS of £135 million results. Clearly this is a very large sum of money and translates into a large number of staff and other resources, notably drugs. But it is put in perspective by the current NHS budget of £15000 million, over 100 times larger. Even a relatively large number of cases of AIDS is still a small resource problem for the NHS. Even a higher number of cases is still only a small part of the wider health problem of the UK. There are, after all, about 27 000 deaths a year in Britain of persons under the age of 50. Over the next 10 years, it is almost impossible to predict which if any new areas of disease will generate demands of 1 or 2% on the NHS.
Of course, the resource problem will be very severe for places which are centres of AIDS treatment. But the problem will develop and the resources gradually be provided, almost certainly at a pace that does not satisfy those treating the patients, but also at a pace that can be managed. From time to time, services will be rationed pending the granting of further resources, just as many other services are. But what further resources should be provided? A number of studies have greatly been proposed to assess the cost of AIDS cases in great detail to answer this question. Apart from the inclusion of overheads, in an attempt to fund other bits of the service under the AIDS umbrella, are these estimates worth having? I would argue that they are not for several reasons.
Firstly, given the great uncertainty about the number of cases, is a refined estimate of the cost per case ofany real use? Districts treating a large number of AIDS cases are likely to have to demonstrate specific services that they are providing to get regional or national funding. General estimates of costs may be relatively unconvincing.
Secondly, the estimates can include very high drug costs. If, as seems likely, AIDS cases increase substantially, to the levels of 5000 or more per year, any drug company with a technical monopoly will be accruing a large amount of income. But the NHS is a monopoly purchaser of drugs and controls prices through an agreement with the industry. No government needs to remain inactive as the drugs bill goes through the ceiling. They can adjust prices for the drugs used to treat AIDS or other drugs from the same company. Over time, competition may also lower the prices of specialized drugs.
Thirdly, the estimates beg questions about what service will be provided. Given that we are probably not doing enough, (and never will) to meet all the needs of terminal and other patients, there are demands which compete with AIDS for money. We provide relatively little counselling for cancer patients, for example, in many parts of the country. While I would like to see more provided, some through wider use of the voluntary sector, I accept that it cannot all be provided. Indeed, we cannot even specify with any clarity how much counselling a case requires, even after extensive data collection. Counselling and support are too personal for that kind of mechanical extrapolation of needs. In practice, AIDS patients will gradually become part of the workload of many groups in hospitals and the community. The time they receive from staff will vary day to day with the other pressures on staff and the needs of AIDS patients. These cannot be specified in advance, but will be managed flexibly as they develop. When staff cannot cope they will ask for more resources. Trying to calculate these resources in advance and in detail when we do not know the number or location of cases is of no help.
Finally, I am concerned that if we continue to emphasize the cost of AIDS we may put it more strongly under scrutiny from the many people who see themselves at no risk of acquiring the disease. This could prove counter-productive, particularly if prevention begins to prove successful. Why advertise how much the disease is costing if it is not going to increase the service but decrease it?
The National Health Service has a limit on the supply side. It has little idea of the exact budget it will receive for new and existing services, but it knows that it is constrained and has limited scope for growth. The service also has little idea of the future demands on it. We know how many elderly people there will be in 10 years' time, but not how well or ill they will be. The service will make its way through the conflicts between supply and demand much as it does now, through compromise and contingency planning. There is ample scope for improving this contingency planning, but with an understanding of alternative scenarios and not detailed information on a single possibility. Changes in treatment will constantly undermine estimates of hospital costs and community care costs can expand to absorb the resources available. Until every sick and disabled person in the community has all the help they think they can use, there will always be pressure for more. the alternative scenarios that may develop in their area. The pace of development is not likely to be so fast that it will swamp their services unexpectedly and service expansion can probably be planned with a relatively short lead time. It is time that we stopped the AIDS research bandwagon from giving us more and more details on services that cannot be specified in time, place or content with any accuracy. Instead, we should concentrate our efforts and research resources on prevention and the best methods of achieving it, both here and in Africa. Waving the spectre of what it might cost to treat is not serving this end or helping to achieve a better service.
